In Vivo Brain Concentrations of N-Acetyl Compounds, Creatine, and Choline in Alzheimer Disease

Adolf Pfefferbaum, MD; Elfar Adalsteinsson, PhD; Daniel Spielman, PhD; Edith V. Sullivan, PhD; Kelvin O. Lim, MD

Background: Alzheimer disease (AD) and normal aging result in cortical gray matter volume deficits. The extent to which the remaining cortex is functionally compromised can be estimated in vivo with magnetic resonance spectroscopic imaging.

Objective: To assess the effects of age and dementia on gray matter and white matter concentrations of 3 metabolites visible in the proton spectrum: N-acetyl compounds, present only in living neurons; creatine plus phosphocreatine, reflecting high-energy phosphate metabolism; and choline, increasing with membrane synthesis and degradation.

Method: Fifteen healthy young individuals, 19 healthy elderly individuals, and 16 patients with AD underwent 3-dimensional magnetic resonance spectroscopic imaging and memory and language testing.

Results: Gray matter N-acetyl compound concentrations (signal intensity corrected for the amount of brain tissue contributing to the magnetic resonance spectroscopic imaging signal) was significantly reduced only in patients with AD, even though both the AD and elderly control groups had substantial gray matter volume deficits relative to the young control group. Both the healthy elderly and AD groups had abnormally high gray matter creatine plus phosphocreatine concentrations. Gray matter choline concentrations were higher in the elderly than the younger controls, and even higher in the AD group than in the elderly control group. Functional significance of these findings was supported by correlations between poorer performance on recognition memory tests and lower gray matter N-acetyl compounds in elderly controls and higher gray matter creatine plus phosphocreatine and choline concentrations in patients with AD.

Conclusion: Cortical gray matter volume deficits in patients with AD are accompanied by disease-related increases in gray matter choline concentrations suggestive of cellular degeneration and reduced N-acetyl compound concentrations, with possible effects on behavioral function.

Arch Gen Psychiatry. 1999;56:185-192
PARTICIPANTS AND METHODS

The 3 study groups included 15 young controls (all men; mean [± SD] age, 25.3 ± 2.9 years), 19 healthy elderly controls (9 men, 10 women; mean age, 73.3 ± 4.1 years), and 16 patients with AD (6 men, 10 women; mean age, 73.4 ± 6.0 years). All analyses were performed blind to subject identity.

The patients with AD were recruited from the Geriatric Psychiatry Rehabilitation Unit and the National Institute of Mental Health Aging Clinical Research Center at the Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif (Table 1). These centers have a 90.2% autopsy-confirmed AD success rate of patients who in life had a diagnosis of probable AD. Patients met National Institute of Neurological and Communicative Diseases and Stroke-Alzheimer’s Disease and Related Disorders Association criteria for probable Alzheimer disease. Controls were recruited from the local community. Subjects were excluded if they had any significant history of psychiatric or neurological disorder unrelated to their diagnosis (stroke, closed head injury), current alcohol or other drug abuse or dependence, or a life-threatening medical condition. Screening included a psychiatric interview and medical examination; informed consent was obtained from all participants (Table 1).

The elderly control and AD groups were matched in age and sex, were comparable in years of education (elderly control mean [± SD], 16.3 ± 2.2 years; AD mean, 15.4 ± 2.0 years), and achieved similar scores on the National Adult Reading Test, an estimate of premorbid intelligence (elderly control mean [± SD], 115.6 ± 5.8; AD mean, 110.6 ± 9.5). Patients with AD (mean [± SD] score, 19.8 ± 4.6) had significantly lower scores than the elderly controls (mean score, 28.3 ± 1.2) on the Mini-Mental State Examination.

NEUROPSYCHOLOGICAL TESTS

Cognitive data were collected within 3 months (0-84 days) of magnetic resonance imaging. Brain-behavior relationships were based on tests assessing verbal and nonverbal recognition and word finding. The Warrington Recognition Test assessed memory for words and faces, and the modified Boston Naming Test assessed confrontation naming.

IMAGE ACQUISITION

In vivo proton MRSI and structural magnetic resonance imaging scans were acquired using a quadrature head coil on a 1.5-T magnetic resonance imaging scanner (GE Signa, Milwaukee, Wis) with echo-speed gradient hardware (GE Medical Systems; Milwaukee, Wis) (2.2-G/cm maximum gradient amplitude, and 185-µs minimum rise time). Data were obtained with oblique anatomic prescriptions parallel to the anteroposterior commissure (AC-PC) line identified from midsagittal structural images. The image acquisition protocol and analysis are given in other studies.

Spectroscopic Image Acquisition

A modified version of a 3-dimensional MRSI sequence using a time-varying readout gradient in the slice selection direction was used to image multiple contiguous slices. Excitation was accomplished with a pair of spin-echo, spectral-spatial pulses preceded by an adiabatic inversion as described in other studies. Collection parameters were repetition time (TR), 2 seconds; inversion time (TI), 170 milliseconds; and echo time (TE), 144 milliseconds. The nominal voxel size was 1.1 cm³ and the total MRSI time was 17 minutes. Data reconstruction and metabolite estimation were performed as described elsewhere. Corrections for receiver gain and coil loading were made when images were reconstructed to allow comparability of metabolite signal levels between subjects. The final metabolite images were 16 images of 32×32 pixels each.

Shimming and Fieldmap Acquisition

An automated shimming procedure with 3 linear terms and 6 nonlinear terms was used to minimize main field variations. A final 3-dimensional fieldmap was collected at a resolution of 64×64×32 voxels (TR, 40 milliseconds; TE, 10 milliseconds; flip angle, 20°; effective slice thickness, 6.4 mm; and field of view, 24 cm) to measure residual field inhomogeneities.

as institutional signal intensity units per tissue volume, revealed more NAc in gray matter than white matter, consistent with many, but not all, studies. Despite significant gray matter volume deficits in elderly healthy individuals, the young and elderly groups had equivalent concentrations of NAc in gray matter and white matter. By contrast, Cr and Cho concentrations demonstrated significant age effects. Cho concentrations were greater in gray matter in older controls; Cr concentrations were greater in gray matter and white matter in older subjects. These observations draw into question the use of Cr and Cho as appropriate references for determining NAc concentration.

We applied our MRSI method to patients with AD and compared their results with those from our study of normal aging. We expected the patients with AD, unlike the healthy elderly controls, to have abnormally low NAc concentrations in gray matter and white matter. We also anticipated that Cho levels would be even higher in patients with AD than they were in healthy elderly controls.

RESULTS

BRAIN TISSUE VOLUMES

The patients with AD had smaller gray matter volumes than the elderly controls, who had smaller volumes than the young controls (F2,49 = 115.904, P = .001). Cerebrospinal fluid volumes showed a complementary stepwise group effect (F2,49 = 70.966, P = .001). The overall group difference was significant for white matter (F2,49 = 3.476, P = .04), but only the AD group exhibited a volume deficit relative to the young and the elderly control groups (Figure 2). The pattern of group differences was virtually identical when examining only those...
A middasgittal, gradient-recalled echo image was used to compute slice positions with 0.5-mm accuracy for all 3 scans in this protocol (anatomical, fieldmap, and MRSI). Anatomic images were acquired with an axial fast-spin echo protocol (TR, 3000 milliseconds; and TE, 20/80 milliseconds; echo train length, 8; 3-mm skip, 0.2 mm: 256 × 256 pixels matrix; field of view, 24 cm; number of excitations, 1; and time, 3 minutes 18 seconds). Sixteen slices were collected, the most inferior slice beginning at the anteroposterior commissure line, corresponding to the 8 middle spectroscopic slices and providing 2 anatomical slices for each MRSI slice. Twelve of these high-resolution images, corresponding to 6 slices of metabolite data, were used in the structure/metabolite analysis.

An average imaging session with the above-described protocol took about 1 hour.

**IMAGE ANALYSIS**

**Spectroscopic Images**

Six MRSI slices were used, beginning with the slice 12.8 mm above the anteroposterior commissure line and extending superiorly. These slices were chosen because they had the least amount of signal loss and artifacts due to field inhomogeneity. Within these 6 slices, only pixels with good homogeneity (B0 shifts within the range of ±5 Hz) were included for analysis. These slices were also manually edited to remove regions, usually outside of the brain, of obvious lipid and/or water artifacts. To further guard against the possibility that incompletely suppressed water signal contaminated the MRSI data, especially for Cho and Cr concentrations in the medial frontal region, an exclusion region roughly corresponding to the cingulate gyrus was constructed for each slice by proportionate geometric positioning. The metabolite signals were calculated as magnitude values, so the noise in the metabolite maps had a noncentral Gaussian (Rician) noise distribution in the low signal-to-noise ratio range. To account for the effects of this noncentral Gaussian noise distribution, a bias correction was applied to the metabolite signal intensity values.

**METABOLITE CONCENTRATION AND TISSUE TYPE**

Despite the significant tissue volume deficit in patients with AD, the number of spectroscopic voxels meeting criteria for analysis did not differ significantly among the 3 groups (F2,39 = 2.399, P = .10). The concentration estimation model provided separate metabolite concentration estimates for gray matter and white matter (Figure 3).

A repeated-measures analysis of variance (3 groups by 2 tissue types) for NAc concentration yielded significant effects of group (F2,47 = 6.913, P = .002) and tissue type (F2,47 = 234.108, P = .001) but no interaction (F2,47 = 1.708, P = .19). The overall group difference was significant in gray matter (F2,49 = 5.283, P = .008); the AD group had significantly lower gray matter NAc levels than the young (P = .03) and elderly (P = .009) control groups, which did not differ from each other. The ratio of gray to white matter NAc concentration was similar for the 3 groups (young control ratio = 1.31; elderly control ratio = 1.38; and patients with AD ratio = 1.30) (F2,49 = 1.024, P = .37).

For Cr concentration, a repeated-measures analysis of variance (3 groups by 2 tissue types) yielded significant group (F2,47 = 21.25, P = .001) and tissue-type effects (F1,47 = 884.214, P = .001) and interaction (F1,47 = 3.934, P = .03). For both tissue types, the elderly controls and patients with AD had higher Cr concentrations than the young controls (elderly vs young controls for gray matter: F1,32 = 4.678, P = .001, and for white matter: F1,32 = 3.935, P = .001; patients with AD vs young controls for gray matter: F1,32 = 4.619, P = .001, and for white matter: F1,32 = 2.572, P = .02). By contrast, the elderly con-
trol and AD groups did not differ significantly from each other in either gray matter ($t_{33} = 1.065, P = .29$) or white matter ($t_{33} = 1.386, P = .18$) Cr concentrations. Again, the ratio of gray matter to white matter Cr concentration was similar for the 3 groups (young control group ratio = 1.98; elderly control group ratio = 1.95; and AD group ratio = 2.12) ($F_{2,49} = 1.503, P = .23$).

For Cho concentrations, a repeated-measures analysis of variance (3 groups by 2 tissue types) yielded a significant group effect ($F_{1,47} = 10.964, P = .001$) and interaction ($F_{2,47} = 12.073, P = .001$) and trend toward a tissue-type effect ($F_{1,47} = 3.691, P = .06$). Gray matter Cho concentrations were lowest in the young controls and highest in the patients with AD, and all group-paired comparisons were significant (young vs elderly: $t_{33} = 3.925, P = .001$; elderly vs patients with AD: $t_{33} = 2.506, P = .02$; young vs patients with AD: $t_{33} = 4.993, P = .001$). As indicated by the interaction, white matter Cho showed a different pattern from gray matter; only the comparison between the elderly controls and patients with AD reached significance; the elderly group had higher Cho concentrations than the AD group ($t_{33} = 3.074, P = .004$). Unlike NAc and Cr, the ratio of gray matter to white matter for Cho concentration showed a group difference, with the value for the AD group higher (ratio = 1.20) than values for the young (ratio = .79, $t_{33} = 4.061, P = .001$) and elderly control (ratio = .91, $t_{33} = 3.362, P = .002$) groups; the young and elderly controls did not differ significantly from each other ($t_{33} = 1.351, P = .19$).

The 3 group-by-metabolite analyses of variance were recalculated excluding women, because the younger group was composed of men only. The results were the same without the women, except that the group-by-Cr interaction was no longer significant in the men-only analysis.

### Table 1. Characteristics of Patients With Alzheimer Disease

<table>
<thead>
<tr>
<th>Subject*</th>
<th>Age, y</th>
<th>Sex</th>
<th>MMSE†</th>
<th>Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/6/92/F</td>
<td>15</td>
<td>F</td>
<td>Nizatidine, donepezil, hydrochlorothiazide, estrogen, Vancenase (beclomethasone dipropionate) nasal spray, aspirin, vitamin supplements</td>
<td></td>
</tr>
<tr>
<td>8/6/F</td>
<td>20</td>
<td></td>
<td>L-Carnitine, estrogen, and over-the-counter health food and vitamin supplements</td>
<td></td>
</tr>
<tr>
<td>10/73/F</td>
<td>24</td>
<td></td>
<td>Lorazepam and over-the-counter vitamin supplements</td>
<td></td>
</tr>
<tr>
<td>5/79/F</td>
<td>15</td>
<td>F</td>
<td>Sertraline hydrochloride, hydrochlorothiazide, lisinopril, levethyroxine sodium, timolol, optic, promethazine hydrochloride, and over-the-counter antibiotics</td>
<td></td>
</tr>
<tr>
<td>6/72/F</td>
<td>18</td>
<td></td>
<td>L-Carnitine, estrogen and acetaminophen</td>
<td></td>
</tr>
<tr>
<td>7/79/M</td>
<td>21</td>
<td></td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>8/84/M</td>
<td>17</td>
<td></td>
<td>Furosemide, estrogen, melazine hydrochloride, and metoprolol</td>
<td></td>
</tr>
<tr>
<td>4/73/M</td>
<td>24</td>
<td>M</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>5/79/F</td>
<td>15</td>
<td>F</td>
<td>Donepezil and vitamin E</td>
<td></td>
</tr>
<tr>
<td>10/73/F</td>
<td>24</td>
<td></td>
<td>Estrogen, donepezil, over-the-counter health food and vitamin supplements</td>
<td></td>
</tr>
<tr>
<td>11/77/F</td>
<td>26</td>
<td></td>
<td>Progesterone, estrogen, folic acid, melatonin, tacrine hydrochloride, hydrochlorothiazide, L-Carnitine, and over-the-counter health food</td>
<td></td>
</tr>
<tr>
<td>6/72/F</td>
<td>18</td>
<td></td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>10/73/F</td>
<td>24</td>
<td></td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>15/71/F</td>
<td>17</td>
<td></td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>16/60/M</td>
<td>28</td>
<td></td>
<td>L-Carnitine</td>
<td></td>
</tr>
</tbody>
</table>

* Patient 3 had Crohn disease; patient 5 had depression; patient 8 had past depression and anxiety; and patient 16 had past alcoholism, with 18 years of sobriety. † MMSE indicates Mini-Mental State Examination.

**Figure 1.** Left, Brain images of a 73-year-old male control. Right, Brain images of a 75-year-old male patient with Alzheimer disease. Superior to inferior brain slices are shown from left to right. Segmented image: the fast spin-echo magnetic resonance structural images are segmented into cerebrospinal fluid (dark gray), gray matter (medium gray), and white matter (light gray). Low-pass tissue image: The tissue image after low-pass filtering matches the spatial frequency characteristics of the metabolite images. The white outlines on these and the specific metabolite images below are taken from the perimeter of the structural images and indicate the registration of the metabolite image with the structural image. Images of N-acetyl compounds, creatine, and choline are of signal intensities that contribute to the quantification of each metabolite concentration.

**CORRELATIONS BETWEEN METABOLITE CONCENTRATIONS AND COGNITIVE TEST SCORES**

As expected, the AD group was impaired on the 3 cognitive measures compared with the elderly controls (Table 3). There were several brain-behavior cor-
relations in the predicted direction. In elderly controls, face recognition scores were positively correlated with gray matter NAc concentration ($t = 0.80, P = .001, n = 13$). In patients with AD, higher Cr gray matter concentrations were related to lower word-recognition scores ($t = -0.67, P = .03, n = 11$), and higher Cho gray matter concentrations were related to lower face recognition scores ($t = -0.70, P = .02, n = 11$).

Independent estimation of the concentrations of NAc, Cr, and Cho revealed different patterns across the groups: NAc showed a disease effect, Cr showed an age effect, and Cho showed disease and age effects. N-Acetyl compounds concentration was significantly reduced only in AD in gray matter but not white matter, even though both

the AD and elderly control groups had substantial gray matter volume deficits relative to the young controls. Both the elderly healthy and AD groups had an excess of Cr in gray matter. Choline concentration in gray matter was notably higher in the elderly than in the young control group, and the AD values were even higher than those measured in the elderly controls.

While neuronal soma and processes may shrink, the current consensus is that little if any loss of neuronal cell numbers occurs in normal aging. Gray matter volume deficits without NAc concentration deficit suggests normal cell integrity in the healthy elderly. Like post-mortem studies, the current in vivo study revealed severe gray matter volume deficits and an accompanying deficit in gray matter NAc concentration in AD.

For literature comparison, we calculated whole brain raw signal intensity NAc/Cr ratio values of 1.382, 1.274, and 1.225 for the young, elderly, and AD groups, respectively. Concentration-corrected ratios of NAc/Cr for gray matter only presented a similar pattern of 1.38, 1.229, and 1.098 for the young, elderly, and AD groups, whereas for white matter only the pattern was 2.073, 1.734, 1.743. Thus, the NAc/Cr ratio differences seen in whole-brain mixed gray-white tissue represent a decrease in the NAc/Cr ratio with aging but no additional AD effect in white matter and a further decrease in this ratio in the AD group in gray matter.

Consistent with other in vivo and postmortem reports, NAc concentration, whether expressed as a ratio of Cr or Cho or in absolute terms, was substantially lower in patients with AD than in age-matched controls. Kwo-On-Yeun et al also noted substantially more reduction in NAc in gray matter than in white matter in comparing patients with AD to controls. As in other studies, NAc signal intensity was greater in gray matter than white matter for all 3 groups in our study.

Across all 3 groups, the calculated Cr concentration in gray matter was almost twice that in white matter, whereas the Cho concentration was more uniformly distributed between gray and white matter. Given these age- and disease-related differences in metabolite con-

### Table 2. Structural Composition (mL) of Brain Generating Magnetic Resonance Spectroscopy Signal (Mean ± SE)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Young Controls</th>
<th>Young Controls vs Elderly Controls</th>
<th>Elderly Controls</th>
<th>Elderly Controls vs Patients With AD*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebrospinal fluid</td>
<td>49.6 ± 2.91</td>
<td>$t_{9} = 6.421, P &lt; .001$</td>
<td>71.3 ± 3.57</td>
<td>$t_{9} = 4.562, P &lt; .001$</td>
</tr>
<tr>
<td>Gray matter</td>
<td>151.9 ± 6.05</td>
<td>$t_{9} = 6.043, P &lt; .001$</td>
<td>106.9 ± 4.58</td>
<td>$t_{9} = 3.756, P &lt; .001$</td>
</tr>
<tr>
<td>White matter</td>
<td>208.0 ± 7.98</td>
<td>$t_{9} = .734, P = .47$</td>
<td>198.4 ± 9.78</td>
<td>$t_{9} = 1.938, P &lt; .07$</td>
</tr>
</tbody>
</table>

#### Without Metabolite Criteria

| Cerebrospinal fluid | 69.8 ± 4.11 | $t_{9} = 8.206, P < .001$ | 124.3 ± 4.92 | $t_{9} = 5.119, P < .001$ | 168.7 ± 7.44 |
| Gray matter | 231.6 ± 4.06 | $t_{9} = 11.52, P < .001$ | 163.3 ± 4.18 | $t_{9} = 4.558, P < .001$ | 132.2 ± 5.21 |
| White matter | 262.1 ± 5.09 | $t_{9} = .294, P = .77$ | 257.9 ± 8.94 | $t_{9} = 1.966, P < .06$ | 234.2 ± 7.76 |

*AD indicates Alzheimer disease.*
centrations for gray and white matter, it is clear that neither Cr nor Cho concentration is constant, and, thus, they should not be used without regard to age and disease effects as referents in ratio expression of the NAc signal. The 3 group comparisons—young controls, elderly controls, and elderly patients with AD—help to disentangle disease effects from effects of normal aging. The former should be superimposed on the latter. Patients with AD did not significantly differ from the elderly controls in the volume of Cr in either gray or white matter, but both groups differed from the young controls. This pattern indicates that increased Cr concentration in patients with AD is attributable to advanced age rather than to the disease. The elevated gray matter Cho concentration in patients with AD, however, seems to be the result of the additive effects of advanced age plus disease. Chang et al noted decreased brain water content (noncerebrospinal fluid) with age, which could explain a relative decrease in cortical volume with the same number of cells, leading to increased metabolite concentration. Miller et al reported that increased choline reflects degree of cellular density in brain tumors. Adding gliosis to this aging effect could explain the additional increase in Cho level we observed in patients with AD. White matter Cho concentration showed the opposite pattern, ie, no increase with age but a decrease with AD. Moats et al observed age-related increases in Cho levels in normal elderly but no further differences between normal elderly and patients with AD. Our observed increased Cho concentration in gray matter may be the result of cell membrane turnover.

Pettegrew et al, using in vitro phosphorus 31 (31P) MRS, found elevated phosphomonoester levels in patients with AD. Brown et al showed that phosphomonoester, phosphomonoester/phosphodiester, and inorganic phosphate levels were elevated in patients with AD compared with controls, whereas no significant differences in any 31P indexes were found by Bottomley et al. Similar findings were reported by Murphy et al. Gonzalez et al reported a 50% increase in phosphomonoester/phosphodiester levels in patients with AD, but unchanged β-nucleoside 5'-triphosphate, phosphocreatine, and inorganic phosphate levels in AD, suggesting that the phosphodiester difference reflected changes in the biophysical state of membrane phospholipids. Using quantitative 31P and 1H perchloric acid extracts, Klunk et al found increased myoinositol, aspartate, L-glutamate, alanine, phosphocholine, and phosphodiester levels, and decreased phosphoethanolamine and NAc-L-aspartate levels. They concluded that compounds related to membrane degradation and excitatory neurotransmission increased in patients with AD, while those related to neuronal integrity and inhibitory neurotransmission decreased. Pettegrew et al reported

Figure 3. Concentrations in gray matter and white matter for each brain metabolite measured. Relative to the elderly control group, the Alzheimer disease (AD) group had lower N-acetyl compounds concentrations in gray matter (*t33 = 2.771, P = .01) but not white matter (t33 = 1.419, P = .17). Creatine was higher in the gray matter of elderly controls (t32 = 4.647, P = .0001) and patients with AD (t32 = 4.804, P = .001) and in the white matter of elderly controls (t32 = 3.603, P = .002) and patients with AD (t32 = 2.133, P = .04) relative to the young controls, showing an age effect. Choline showed an additive age and disease effect for gray matter (# young vs elderly: t32 = 3.847, P = .02; elderly vs AD: t29 = 2.552, P = .005). Error bars indicate SEMs.

Table 3. Scores on Cognitive Tests

<table>
<thead>
<tr>
<th>Tests</th>
<th>Mean (SE)</th>
<th>No. of Subjects</th>
<th>Elderly Controls Patients With AD*</th>
<th>Patients With AD†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modified Boston Naming Test</td>
<td>38.3 (1.2)</td>
<td>8</td>
<td>27.97, P&lt; .02</td>
<td>28.3 (2.9)</td>
</tr>
<tr>
<td>Warrington Recognition Test</td>
<td>46.8 (1.1)</td>
<td>13</td>
<td>8.421, P&lt; .001</td>
<td>30.2 (1.7)</td>
</tr>
<tr>
<td>Words</td>
<td>42.3 (1.2)</td>
<td>13</td>
<td>4.673, P&lt; .001</td>
<td>31.3 (2.2)</td>
</tr>
<tr>
<td>Faces</td>
<td>42.3 (1.2)</td>
<td>13</td>
<td>4.673, P&lt; .001</td>
<td>31.3 (2.2)</td>
</tr>
</tbody>
</table>

* AD indicates Alzheimer disease.
† n = 11.
increased phosphomonoester and phosphocreatine levels that preceded dementia for 1 subject.

The proton Cr signal is a combination of phosphocreatine and creatine.8 Thus, one cannot separate the contribution of creatine and phosphocreatine to the total Cr signal or relate findings directly to phosphorus spectroscopy studies, which, for instance, report a decreased ratio of phosphocreatine to inorganic orthophosphate in AD.” Similarly, several Cho-containing compounds contribute to the Cho peak in proton magnetic resonance spectroscopy. As reviewed by Michaelis et al82 Cho plas-

collection of phosphomonoester and phosphocreatine lev-

e ates with short T2 relax-

to the total Cr signal. Contributions from 15- to 18-
mol/L lipid-soluble phosphatidylcholine are mi-

REFERENCES

7. Sommers HS, Partanen K, Pikkanen A, Vainio P, Hamalainen T, Halikainen M, Koivistoinen P, Kiekkas P. Volumetric MRI analysis of the amygdala and the hippocam-
8. Seib JP, Jagust WJ, Wong STS, Roos MS, Reed BR, Budinger TF. Quantitative NMR measurements of hippocampal atrophy in Alzheimer’s disease. Magn Re-
9. Boraus C, Hof PR, Morrison JH. Neurofibillary tangle densities in the hippo-
15. Hof PR. Morphology and neurochemical characteristics of the vulnerable neu-

18. Braak H, Braak E. Morphometric criteria for the recognition of Alzheimer’s disease and the distribution pattern of cortical changes related to this disorder. Neu-

19. Regeur L, Jensen GB, Pakkenberg H, Evans SM, Pakkenberg B. No global neo-
cortical neuronal loss in brains from patients with senile dementia of Alzhei-
23. Blatter DD, Bigler ED, Gale SD, Johnson SC, Anderson C, Burnett BM, Parker N, Kurth S, Horn S. Quantitative volumetric analysis of brain MRI: normative data-
24. Jernigan TL, Archibald SL, Berhow MT, Sowell ER, Foster DS, Hasselink JW. Ce-

26. Tang Y, Nyengaard JR, Pakkenberg B, Gundersen HJG. Age-induced white-

29. Flood DG. Critical issues in the analysis of dendritic extent in aging humans, pri-

31. Ernst T, Chang L, Melchor R, Mehringer CM. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 NMR spectroscopy. Ra-

32. Schuff N, Amend D, Ezeikel F, Steinman SK, Tanabe J, Norman D, Jagust W, Kra-

mer JH, Mistrain JA, Fein G, Weiner MW. Changes of hippocampal N-acetyl-
aspartate and volume in Alzheimer’s disease: a proton MR spectroscopic imag-

33. Klunk WE, Paehling K, Berry J, McClure RJ, Petetree JW. N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer’s disease: a prelimi-


